NEW YORK (GenomeWeb News) – Quest Diagnostics has struck multi-year agreements with both Illumina and Life Technologies to use their respective sequencing technologies for clinical testing, the firms said today.

Under two separate agreements, Quest will have the right to develop and offer molecular laboratory-developed tests using Illumina's MiSeq and Life Tech's Ion Torrent platforms and the respective related reagents for clinicians and clinical trials performed by its pharmaceutical and biotechnology clients.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.